Is Hydroxychloroquine Effective in Treating Primary Sjogren's Syndrome: a Systematic Review and Meta-analysis

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2017 May 14

PMID 28499370

Citations 38

Authors

Shi-Qin Wang

Li-Wei Zhang

Pan Wei

Hong Hua

Affiliations

Soon will be listed here.

Abstract

Background: To systematically review and assess the efficacy and safety of hydroxychloroquine (HCQ) for treating primary Sjogren's syndrome (pSS).

Methods: Five electronic databases (Pubmed, EMBASE, Web of science, Ovid, Cochrane Library) were searched for randomized controlled trials and retrospective or prospective studies published in English that reported the effect of HCQ on pSS. The subjective symptoms (sicca symptoms, fatigue and pain) and the objective indexes (erythrocyte sedimentation rate and Schirmer test) were assessed as main outcome measures. A meta-analysis and descriptive study on the efficacy and safety of HCQ were conducted. The estimate of the effect of HCQ treatment was expressed as a proportion together with 95% confidence interval, and plotted on a forest plot.

Results: Four trials with totals of 215 SS patients, including two randomized controlled trials, one double blind crossover trial and one retrospective open-label study, were analyzed in this review. For dry mouth and dry eyes, the effectiveness of HCQ treatment was essentially the same as placebo treatment. For fatigue, the effectiveness of HCQ was lower than placebo. The efficacy of HCQ in treating pain associated with pSS was superior to that of the placebo. There was no significant difference between HCQ-treated groups and controls in terms of Schirmer test results, but HCQ could reduce the erythrocyte sedimentation rate compare with placebo. A descriptive safety assessment showed that gastrointestinal adverse effects were the most common adverse effects associated with HCQ.

Conclusions: This systematic review showed that there is no significant difference between HCQ and placebo in the treatment of dry mouth and dry eye in pSS. Well-designed, randomized, controlled trials are needed to provide higher-quality evidence to confirm our findings, and future studies should focus on some other index or extraglandular measures, such as cutaneous manifestations, to further explore the therapeutic effect of HCQ in pSS.

Citing Articles

Hydroxychloroquine: A double‑edged sword (Review).

Huo R, Wei C, Yang Y, Lin J, Huang X Mol Med Rep. 2025; 31(4).

PMID: 39981928 PMC: 11868775. DOI: 10.3892/mmr.2025.13467.

Improved Fatigue Management in Primary Sjögren's Syndrome: A Retrospective Analysis of the Efficacy of Methotrexate in Chinese Patients.

Zhou M, Dai X, Yuan F J Inflamm Res. 2024; 17:7551-7560.

PMID: 39464343 PMC: 11505384. DOI: 10.2147/JIR.S475605.

Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions: A Meta-Analysis.

Salcher-Konrad M, Nguyen M, Savovic J, Higgins J, Naci H JAMA Netw Open. 2024; 7(9):e2436230.

PMID: 39331390 PMC: 11437387. DOI: 10.1001/jamanetworkopen.2024.36230.

G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome.

Fang R, Zhou Z, Chu R, Guan Q, He F, Ge M Acta Pharmacol Sin. 2024; 45(12):2611-2624.

PMID: 39054339 PMC: 11579508. DOI: 10.1038/s41401-024-01350-4.

Deciphering the immunological interactions: targeting preeclampsia with Hydroxychloroquine's biological mechanisms.

Gajic M, Schroder-Heurich B, Mayer-Pickel K Front Pharmacol. 2024; 15:1298928.

PMID: 38375029 PMC: 10875033. DOI: 10.3389/fphar.2024.1298928.

References

Tishler M, Yaron I, Shirazi I, Yaron M . Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999; 58(4):253-6. PMC: 1752865. DOI: 10.1136/ard.58.4.253. View

Suarez-Almazor M, Belseck E, Shea B, Homik J, Wells G, Tugwell P . Antimalarials for rheumatoid arthritis. Cochrane Database Syst Rev. 2000; (2):CD000959. PMC: 8407035. DOI: 10.1002/14651858.CD000959. View

Venables P . Sjögren's syndrome. Best Pract Res Clin Rheumatol. 2004; 18(3):313-29. DOI: 10.1016/j.berh.2004.02.010. View

Fox R . Sjögren's syndrome. Lancet. 2005; 366(9482):321-31. DOI: 10.1016/S0140-6736(05)66990-5. View

Fox P . Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007; 1098:15-21. DOI: 10.1196/annals.1384.003. View

Mackay F, Groom J, Tangye S . An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol. 2007; 19(5):406-13. DOI: 10.1097/BOR.0b013e328277ef4c. View

Bostrom E, Forsblad dElia H, Dahlgren U, Simark-Mattsson C, Hasseus B, Carlsten H . Salivary resistin reflects local inflammation in Sjögren's syndrome. J Rheumatol. 2008; 35(10):2005-11. View

Ioannidis J . Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008; 14(5):951-7. DOI: 10.1111/j.1365-2753.2008.00986.x. View

Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta M . Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2008; 69(1):20-8. DOI: 10.1136/ard.2008.101766. View

10.

Forsblad-dElia H, Carlsten H, Labrie F, Konttinen Y, Ohlsson C . Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab. 2009; 94(6):2044-51. DOI: 10.1210/jc.2009-0106. View

11.

Nikolov N, Illei G . Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol. 2009; 21(5):465-70. PMC: 2766246. DOI: 10.1097/BOR.0b013e32832eba21. View

12.

Chiorini J, cihakova D, Ouellette C, Caturegli P . Sjögren syndrome: advances in the pathogenesis from animal models. J Autoimmun. 2009; 33(3-4):190-6. PMC: 3439154. DOI: 10.1016/j.jaut.2009.09.009. View

13.

Yavuz S, Asfuroglu E, Bicakcigil M, Toker E . Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. Rheumatol Int. 2010; 31(8):1045-9. DOI: 10.1007/s00296-010-1415-4. View

14.

Roescher N, Tak P, Illei G . Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis. 2010; 69(6):945-8. PMC: 3044243. DOI: 10.1136/ard.2009.115378. View

15.

Cankaya H, Alpoz E, Karabulut G, Guneri P, Boyacioglu H, Kabasakal Y . Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110(1):62-7. DOI: 10.1016/j.tripleo.2010.02.032. View

16.

Ramos-Casals M, Tzioufas A, Stone J, Siso A, Bosch X . Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010; 304(4):452-60. DOI: 10.1001/jama.2010.1014. View

17.

Ter Borg E, Risselada A, Kelder J . Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjögren's Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum. 2010; 40(6):547-51. DOI: 10.1016/j.semarthrit.2010.07.006. View

18.

Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X, Tzioufas A . Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol. 2012; 8(7):399-411. DOI: 10.1038/nrrheum.2012.53. View

19.

Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X . Primary Sjogren syndrome. BMJ. 2012; 344:e3821. DOI: 10.1136/bmj.e3821. View

20.

Liang Y, Yang Z, Qin B, Zhong R . Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2013; 73(6):1151-6. DOI: 10.1136/annrheumdis-2013-203305. View